NCT00072670 - A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

September 30, 2008

Study Completion Date

November 30, 2008

Conditions

Prostate Cancer

Interventions

DRUG

Trabectedin

Trabectedin will be administered intravenously as either 0.58 milligram per square meter (mg/m\^2) weekly as 3-hour infusion or 1.5 mg/m\^2 or 1.2 mg/m\^2 every three weeks as 24-hour infusion until disease progression or unacceptable toxicity.

Trial Locations (1)

02114-2617

Massachusetts General Hospital, Boston